Search results
Results from the WOW.Com Content Network
Yoshihide Suga, the prime minister of Japan vaccinated with a COVID-19 vaccine. COVID-19 vaccination in Japan started later than in most other major economies. [4] The country has frequently been regarded as "slow" in its vaccination efforts. [5] [6] Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use.
The COVID-19 vaccination in Japan began on 17 February 2021, more than a month after the first anniversary of the beginning of the pandemic in the country was commemorated. As of 22 October 2021, about 96.4 million people in Japan received at least one dose of the COVID-19 vaccine, while about 86.9 million were fully vaccinated.
Kyoto Prefecture: 6877 84 Osaka Prefecture: 38095 742 Hyōgo Prefecture: 13809 307 Chūgoku Okayama Prefecture: 2071 16 Tottori Prefecture: 177 2 Shimane Prefecture: 235 0 Hiroshima Prefecture: 4397 71 Yamaguchi Prefecture: 833 5 Shikoku Kagawa Prefecture: 528 5 Tokushima Prefecture: 291 9 Kōchi Prefecture: 770 13 Ehime Prefecture: 811 14 Kyushu
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Metropolitan Tokyo asked some businesses to close and the ancient capital of Kyoto warned tourists to stay away as Japan battles a fast-spreading outbreak of the new coronavirus, amid fears the ...
Bank of Kyoto, a regional lender based in the ancient Japanese city, has a unique buffer against the hit to tourism from the coronavirus - dividends from local high-tech heavyweights. After ...
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, [39] [42] such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be [needs update] prioritized distribution first within the UK and to the ...